This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) (NAFLD)

This study has been terminated.
Information provided by (Responsible Party):
Manal Abdelmalek, Duke University Medical Center Identifier:
First received: August 13, 2008
Last updated: December 5, 2016
Last verified: December 2016
The purpose of this study is to find out if Metformin is safe and useful in the treatment of NAFLD.

Condition Intervention Phase
Fatty Liver Drug: Glucophage (Metformin) Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Hyperinsulinemia and Insulin Resistance in Nonalcoholic Fatty Liver Disease. Metformin for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial

Resource links provided by NLM:

Further study details as provided by Manal Abdelmalek, Duke University Medical Center:

Primary Outcome Measures:
  • Study Endpoints Will Include Measurements of Insulin Sensitivity, Hepatic Insulin Clearance, and Altered Parameters of Lipid Metabolism, Changes in the Histological Features That Define NAFLD, and Quantitative Measurements of Visceral and Peripheral Fat. [ Time Frame: 24 months ]

Secondary Outcome Measures:
  • Tests the Postulate That Metformin Will Improve Insulin Sensitivity in NAFLD. Also Test the Postulate That Improving IR (Insulin Resistance) With an Insulin Sensitizing Agent Will Improve Biochemical and Histological Features of NAFLD. [ Time Frame: 24 months ]
  • Determine if Metformin Improves the Altered Parameters of Lipid Metabolism as Compared to Placebo. [ Time Frame: 24 months ]
  • Measure the Differential Effects of IR and Lipid Metabolism on Peripheral Mononuclear Cell (PBMC) Inflammatory Response and the Associated Hepatocyte Mitochondrial Ultrastructure and Measures of Oxidative Stress [ Time Frame: 24 months ]

Enrollment: 11
Study Start Date: April 2009
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Metformin
Metformin XR (extended-release) 2000 mg daily
Drug: Glucophage (Metformin)
metformin XR 2000 mg daily for 12 months
Other Names:
  • metformin
  • Glucophage XR (extended-release)
  • Glumetza
  • Fortamet
  • Riomet
Placebo Comparator: Placebo
Placebo capsule
Drug: Placebo
placebo 2000 mg daily for 12 months

Detailed Description:
NAFLD is a poorly understood disease which may cause an enlarged liver, abnormal liver test results, and scarring of the liver. It may occur more often in people with obesity, high levels of cholesterol (blood fats), diabetes (high blood sugar), or the insulin resistance syndrome (where a person's body does not respond to the hormone insulin which helps keep blood sugar levels normal). Currently, no effective drug treatment for NAFLD exists. There is increasing evidence that NAFLD may be a condition due to a problem with metabolism (the way your body uses energy). Previous studies have shown that high glucose (sugar) levels may play an important role in the development of fatty liver disease. Medications that decrease your natural glucose level may reduce the amount of fat in the liver and, therefore, might be useful in the treatment of NAFLD. Metformin, a drug approved by the U.S. Food and Drug Administration (FDA) for use in patients with diabetes, has been shown to improve fatty liver in animals and in a small number of human beings.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • biopsy-proven NAFLD, determined within 12 months of study initiation

Exclusion Criteria:

  • > 20 grams of alcohol/day
  • impaired oral glucose tolerance test
  • known diagnosis of diabetes mellitus
  • hepatitis C infection
  • cirrhosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00736385

United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Manal Abdelmalek
Principal Investigator: Manal F Abdelmalek, MD, MPH Duke University Medical Center, Department of Medicine, Division of Gastroenterology
  More Information

Responsible Party: Manal Abdelmalek, Associate Professor of Medicine, Duke University Medical Center Identifier: NCT00736385     History of Changes
Other Study ID Numbers: Pro00006196
K23DK062116 ( US NIH Grant/Contract Award Number )
Study First Received: August 13, 2008
Results First Received: March 17, 2015
Last Updated: December 5, 2016

Keywords provided by Manal Abdelmalek, Duke University Medical Center:
nonalcoholic fatty liver disease

Additional relevant MeSH terms:
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on June 23, 2017